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Introduction
Over the past decades considerable methodological
and logistic advances in outof hospital resuscitation have
been achieved but the overall prognosis of cardiac arrest is
still poor. In search of new therapeutic options, attention
has been directed to the use of fibrinolytic drugs applied
during cardiopulmonary resuscitation [2]. There are two
major arguments in support of this concept. One is the
reversal of macrovascular occlusions associated with
myocardial infarction and pulmonary embolism which
account for approximately 70% of all cardiac arrest cases
[3]. The other is amelioration of microcirculatory obstruc
tions resulting from disseminated coagulopathy which
develops after circulatory arrest due to an imbalance
between coagulation and fibrinolysis [4]. The latter is of
particular importance for the brain because it may con
tribute to the noreflow phenomenon which is thought to
limit neurological recovery after cardiac arrest exceeding
8—10 min duration [5]. 
Many case reports and several smallnumber thera
peutic studies using urokinase, streptokinase, alteplase,
rtPA or the recently developed tPA isomer tenecteplase are
in support of this concept [6—16]. Interestingly, these
reports included not only a high rate of return of sponta
neous circulation (ROSC) but also a surprisingly high
number of neurologically intact survivors, even after pro
longed cardiopulmonary resuscitation (CPR) [17].
Several small prospective and uncontrolled studies sug
gested a beneficial effect of thrombolytic drugs adminis
tered during CPR in patients suffering from acute massive
pulmonary embolism [18], acute myocardial infarction [19]
and in patients who had been unresponsive to convention
al resuscitation efforts [20]. In a prospective study in out
ofhospital cardiac arrest patients, we have compared
patients treated with heparin and alteplase and patients
with standard therapy, if ROSC was not achieved within 15
minutes of conventional CPR [9]. Patients treated with
alteplase were more likely to achieve ROSC and hospital
admission compared to controls. This were supported by a
largescale retrospective casecontrol study in 324 outof
hospital cardiac arrest patients demonstrating a hospital
discharge rate of 25% vs. 15% [21].
An inherent risk of thrombolytic treatment is bleed
ing. A metaanalysis of thrombolysis during CPR did not
reveal an increase of significant bleedings [22] but in view
of the potential risk of such complications, and as several
studies did not confirm improvement of outcome [23—25],
a multicenter randomized doubleblind, placebocontrolled
trial (The Thrombolysis in Cardiac Arrest (TROICA)
study) has been carried out [1,26]. The TROICA trial is a
European multicenter trial with 1,050 patients suffering
from witnessed outofhospital cardiac arrest of presumed
cardiac origin. Patients were randomized to a weight
adjusted dose of tenecteplase or placebo during CPR, with
out any concomitant anticoagulant therapy. Interestingly,
there were no differences between tenecteplase and placebo
in 30day survival (15% vs. 17%), ROSC and hospital
admission. There were also no significant differences in
cerebral outcome, but there was a trend towards a higher
number of patients with good cerebral recovery, i.e. cerebral
performance categories 1 or 2, in the tenecteplase group
(63% vs. 56%) [1].
All this raises the question to what extent cerebral
noreflow affects neurological recovery after cardiac arrest,
and if it does so, whether thrombolysis can be expected to
prevent this complication. In this communication experi
mental data dealing with this question are reviewed.
Noreflow of the brain after cardiac arrest
The noreflow phenomenon was first described by
Ames et al. who studied the recirculation of the brain after
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increasing durations of global cerebrocirculatory arrest by
staining the blood with carbon black prior to reperfusion
[27]. Cerebrocirculatory arrest was induced in rabbits by
inflating a pneumatic cuff placed around the neck of the
animals to above arterial blood pressure, and reperfusion
was initiated by releasing the pressure from the cuff. The
investigation was prompted by the observation that in the
isolated retina evoked potentials fully recovered in vitro
after up to 20 min glucose and oxygen deprivation at 37°C
[28] whereas normothermic circulatory arrest in vivo led to
irreversible brain injury within less than 8—10 min [29].
Assuming that the anoxic sensitivity of retinal neurons is
similar to that of the brain, Ames and his colleagues
hypothesized that the difference must be related to the vas
cular system and that reoxygenation in vivo by the circu
lating blood is less efficient than the restoration of oxygen
supply in vitro. The results confirmed that with increasing
duration of ischemia in vivo an increasing part of the brain
was not recirculated with blood: after 7.5 min circulatory
arrest up to 50% and after 15 min up to 95% of brain vol
ume suffered noreflow [27]. As the shortest ischemia time
at which substantial noreflow became prominent, i. e. 7.5
min, came close to the previously established limits of brain
tolerance to circulatory arrest, the authors concluded, that
the high vulnerability of the brain to ischemia might be due
to secondary postischemic hemodynamic rather than to
primary ischemic cellular dysfunction. 
Further studies into the mechanisms of noreflow
revealed that that this disturbance is a microvascular disor
der caused by the combination of endothelial and perivas
Fig. 1: Pattern of noreflow in cat brain after successful resuscitation from 5, 15 and 30 min cardiac arrest. Noreflow (black)
areas were visualized 30 min after return of spontaneous cardiac function by labeling circulating blood with FITCalbumin.
Modified from [32].
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cular glial swelling, an increase in blood viscosity due to
intravascular coagulation, hemoconcentration and aggre
gation of platelets at low shear, and the formation of
endothelial blebs derived from protrusions of endothelial
cells (for review see [5, 30]). The combined effect of these
alterations is an increase in microvascular resistance which
can only be overcome by an increase in postischemic reper
fusion pressure. Using the pneumatic cuff method for the
production of cerebrocirculatory arrest, the reperfusion
pressure required to prevent noreflow amounts to about
60 mmHg after 10 min ischemia, 80 mmHg after 15 min
ischemia and over 160 mmHg after 30 min ischemia [31].
This relationship is the reason that noreflow is of
particular concern for cardiac arrest where conventional
resuscitation procedures may not be able to built up the
blood pressure required for reperfusion, particularly after
longer durations of ischemia. Several experimental studies
are in support of this assumption. Fischer et al. induced
ventricular fibrillation in cats , using internal bipolar elec
trical stimulation [32]. After 5, 15 or 30 min cardiac arrest,
advanced cardiopulmonary resuscitation was carried out
by closedchest cardiac massage in combination with
mechanical ventilation with 100% oxygen and the intra
venous infusion of 0.2 mg/kg epinephrine and 2 mEq/kg
sodium bicarbonate. Electrical defibrillation was attempt
ed 4 min later and — if unsuccessful — repeated after addi
tional 2—3 min periods of cardiac massage and 0.1 mg/kg
epinephrine injections. Reperfusion of the brain was visual
ized by labeling the circulating blood with fluoresceine
isothiocyanate (FITC)albumin, and areas of noreflow
were defined as absence of microvascular filling. The filling
defects were identified by fluorescence microscopy at 8
standard coronal levels of forebrain, and expressed as per
cent of total sectional area. During cardiac massage no
reflow affected 21%, 42% and 70% of forebrain after 5, 15
and 30 min cardiac arrest, respectively. Following success
ful resuscitation of the heart and 30 min spontaneous recir
culation at mean arterial pressure of about 80 mmHg, no
reflow resolved only after 5 min cardiac arrest to 7%
(p<0.05) but persisted in 30% and 65% of forebrain after 15
and 30 min cardiac arrest, respectively (n. s.) The topical
distribution of noreflow areas was multifocal and exhibit
ed a timedependent centripetal expansion with increasing
ischemia time (Fig. 1). After 5 min cardiac arrest it mainly
affected hippocampus and multiple small areas in basal gan
glia, after 15 min it expanded into cerebral cortex, and after
30 min all parts of the brain were involved.
The importance of the initial postischemic reperfu
sion pressure for the manifestation of noreflow was also
documented by Böttiger et al. [33] who induced cardiac
arrest in rats by electrical ventricular fibrillation and com
pared resuscitation by basic life support, i.e. mechanical ven
tilation and external cardiac compression, with advanced
resuscitation procedures, in which epinephrine and sodium
bicarbonate were applied additionally to accelerate the
return of functionally efficient reperfusion pressure. During
basic life support mean arterial blood pressure amounted to
27 mmHg, and during advanced resuscitation procedures to
about 65 mmHg. 12 min cardiac arrest followed by 5 min
basic life support before advanced resuscitation was started
resulted in noreflow in 6.9% of brain volume, whereas car
diac arrest of 17 min followed immediately by advanced
resuscitation reduced noreflow to 0.7% (p<0.05).
Resuscitation at high perfusion pressure, therefore, appears
to be beneficial even if ischemia time is prolonged.
This explains occasional reports on successful brain
resuscitation after normothermic cardiac arrest of up to 30
min when reperfusion pressure was raised by either vigor
ous intrathoracic cardiac massage [34], or by using
mechanical extracorporeal circulation [35,36]. Brain reper
fusion at elevated blood pressure level was also carried out
by Seo et al. using the socalled twostage resuscitation
protocol [37]. In this experiment cats were submitted to 30
min KClinduced cardioplegia, followed by closed chest
cardiac massage. During cardiopulmonary resuscitation the
brain was disconnected from the general circulation by
inflating a pneumatic cuff around the animal's neck until
spontaneous circulation with systolic blood pressure over
100 mmHg returned. Although this procedure prolonged
the ischemia time of the brain from 30 min to as long as 1
hour, regional energy metabolism returned to normal in 6
out of 13 animals, indicating not only successful prevention
of noreflow but also functional recovery [37]. Finally,
reflow at high reperfusion pressure was extensively investi
gated in a model of prolonged selective brain ischemia. In
this model brain circulation was completely interrupted by
intrathoracic occlusion of the innominate, subclavian and
internal mammary arteries in combination with pharmaco
logically induced hypotension. As the heart was not affect
ed by this procedure, systolic arterial blood pressure could
be raised pharmacologically well over 200 mm Hg prior to
vessel release, resulting in instantaneous reperfusion and
the development of pronounced hyperemia. Prevention of
noreflow was associated with successful metabolic, elec
trophysiological and even neurological brain recovery and
could be achieved without any further interventions after
normothermic circulatory arrest of up to 1 hour [38]. The
combined evidence of these data suggests that the high
incidence of brain injury after much shorter periods of car
diac arrest is, in fact, due to cerebral noreflow, and that
prevention of noreflow is a reasonable strategy to improve
neurological outcome.
Contribution of disseminated
coagulopathy to noreflow
The proposition of the contribution of microvascu
lar coagulation to the development of noreflow is infer
ential and mainly based on the observation that cerebro
circulatory arrest induces disseminated intravascular
coagulation (DIC) [4,39—43]. In our laboratory one
hour selective brain ischemia induced pronounced con
sumption coagulopathy with dramatic decrease in the
blood content of platelets and fibrinogen that was asso
ciated with reciprocal prolongation of coagulation times
(Fig. 2) [44]. 
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DIC is a multifactorial process triggered by
ischemic/hypoxic damage of the endothelium, thereby
exposing pathological levels of tissue factor. By inducing
intrinsic and extrinsic activation of the coagulation cascade
an uncontrolled generation of thrombin leads to systemic
fibrin deposition in the noncapillary microvasculature. In
addition platelets are activated, mainly via the thrombox
ane A2pathway to form platelet aggregates, which further
impair the microcirculation. There is also clear indication
of a systemic inflammatory response as evidenced by acti
vation of neutrophils. Interestingly, patients with acute
coronary syndrome, who are at high risk of cardiac arrest,
exhibit a pronounced hypercoagulable state already before
the ischemic event, as demonstrated by increased levels of
thrombinantithrombin complex (TATcomplex) and of
plasminogen activator inhibitor1 (PAI1). These changes
reflect the increased turnover in thrombin, being inactivat
ed by the formation of TATcomplexes, on the one hand,
and by impaired fibrinolysis due to high concentration of
PAI1, on the other. The latter is released in excess from the
damaged endothelial cells to inhibit cleavage of the fibrin
clots by plasmin [45]. 
The only study which directly addressed the relation
ship between DIC and cerebral blood flow came from our
laboratory and was carried out in cats submitted to 1 hour
complete cerebrocirculatory arrest [46]. To detect microag
gregates of platelets after reperfusion, platelets were labelled
with 51Cr. Blood volume was measured by injection of
125Iodinealbumin and the blood platelet count, together
with serum fibrinogen, was determined in venous blood
taken before ischemia and after reperfusion for 30 min, 2
hours and 4 hours, respectively. The number of platelets
entrapped in brain and peripheral organs was calculated by
subtracting from the total tissue platelet count those con
tained in the circulating blood, as derived from the tissue
blood content measured with 125Ialbumin. Thirty minutes
after the beginning of postischemic recirculation the num
ber of entrapped platelets increased significantly in the
whole brain, the highest number being found in the border
zones and in the cerebellum. After 4 hours platelets were
almost completely washed out of the brain but high numbers
of aggregated platelets were detected in the kidney, the lung
and the liver throughout the observation time. In the liver
even a continuous increase was observed, possibly due to
phagocytosis of platelets and platelet fragments by the retic
uloendothelial system (RES).
Interestingly, cerebral platelet aggregation did not
result in ischemia but, quite contrary, was most pronounced
at the time of postischemic hyperemia [46]. This is
explained by the builtup of a high reperfusion pressure
after selective cerebrocirculatory arrest which led to the
restoration of blood circulation to most parts of cerebral
microcirculation and which is in line with the observation
that cerebral noreflow can be prevented by raising blood
Fig. 2: Disseminated coagulopathy following 1 hour cerebrocirculatory arrest induced in cat by intrathoracal clamping of the
brachiocephalic and subclavian arteries. Note progressive reduction of platelets and fibrinogen in the circulating blood asso
ciated with reciprocal lengthening of the clotting times. Modified from [44].
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reperfusion pressure above normal [31]. After cardiac arrest
the situation is presumably different because during car
diac resuscitation reperfusion pressure is distinctly below
normal. To the best of our knowledge experimental data are
not available to document the contribution of intravascular
coagulation to noreflow under this circumstance, but even
in the absence of such a direct involvement, intravascular
coagulation may be detrimental. As platelets accumulate
massively in peripheral organs, notably in the lung, the kid
ney and the liver, multiorgan failure may develop which
might be of similar significance for the functional outcome
of postcardiac arrest brain resuscitation as the direct
involvement in postischemic reperfusion. Prevention of
disseminated coagulation may, therefore, be of considerable
therapeutic interest irrespective of its putative role in the
pathophysiology of noreflow. 
Thrombolytic treatment of noreflow
An important motivation for thrombolysis during
cardiac resuscitation is prevention of cerebral noreflow
but the first attempts to improve neurological outcome by
anticoagulation were made well before the noreflow phe
nomenon had been discovered.
Already in the middle of the last century, Crowell
demonstrated beneficial effects of heparin treatment before
cardiac arrest. Only very few dogs survived without
heparin pretreatment, while the survival rate was 16% and
67%, respectively, when a dose of 2 mg and 5 mg per kg
body weight of heparin was given [47]. Crowell also
demonstrated beneficial effects of pretreatment with
thrombolytic agents. In the control group, 14 of 15 animals
died after 15 min of cardiac arrest [48]. The surviving ani
mal suffered from severe neurological damage. In contrast,
only 2 of 14 animals died if streptokinase had been admin
istered before cardiac arrest, and almost all neurological
deficits in this group disappeared within 2 months. Some
years later, Lin demonstrated that the administration of
streptokinase combined with dextran reduces the duration
of a flat line EEG and improves cerebral blood flow after
cardiac arrest in dogs [49]. Safar and his group observed an
improved neurological recovery in dogs receiving heparin,
dextran and hypertensive reperfusion following cardiac
arrest [50]. In accordance with these findings, a post
mortem study in humans revealed intravascular fibrin for
mation in pulmonary and renal microvessels following
resuscitation from cardiocirculatory arrest, but not in
patients who died without CPR [51]. These data suggest
that there is indeed an imbalance in hemostasis during
reperfusion after cardiac arrest that can lead to intravascu
lar fibrin generation and microthrombosis in the microcir
culation of all organs including the brain. 
Experimental evidence that fibrinolysis reduces no
reflow has been provided only in one animal investigation
(Table) [52]. In this study cats were submitted to 15 min
ventricular fibrillation, followed by advanced cardiopul
monary resuscitation with or without the additional appli
cation of rtPA and heparin. Cardiac arrest was induced by
electrical fibrillation and cardiopulmonary resuscitation by
extrathoracal cardiac massage in combination with repeat
ed injections of epinephrine and sodium bicarbonate. 30
min after the onset of cardiac resuscitation microvascular
perfusion was assessed by staining the circulating blood
with fluoresceine isothiocyanate (FITC)albumin, and no
reflow was identified by the absence of microvascular fill
ing. Thrombolysis significantly reduced the extent of no
reflow from 28% to 7% of brain volume, reflecting the
substantial reversal of microthrombotic occlusions.
Obviously, this finding provides a plausible explanation for
thrombolysisinduced improvement of neurological recov
ery under experimental [48, 49] and clinical conditions [8,
14, 15, 53]. However, blood reperfusion may also improve
due to other rtPAinduced effects such as the improvement
of inotropic heart function [52] or the change in blood vis
cosity [54]. Thrombolysis is, therefore, not the only strate
gy for improving postischemic recirculation and should be
evaluated in comparison to other, possibly less hazardous
interventions. 
Conclusions
In the TROICA trial the fibrinolytic agent
tenecteplase, without concomitant anticoagulatory inter
vention, did not significantly improve cerebral outcome or
the overall survival rate after outofhospital cardiac arrest.
However, this does not necessarily refute the concept of
thrombolytic amelioration of cerebral noreflow because
the postulated neurological improvement may show up
only when cerebral noreflow becomes the limiting factor
for brain resuscitation, i. e., after circulatory arrest of longer
than 8—10 minutes. In the light of a trend towards better
overall neurological recovery in the tenecteplase group of
the TROICA trial, it would be of interest to reevaluate the
neurological recovery in subgroups of patients with differ
ent durations of ischemia.
It is also conceivable that the experimentally docu
mented thrombolytic alleviation of noreflow was not
mediated by reversal of intravascular coagulation but by
reduction of blood viscosity which is known to improve
postischemic recirculation. If the latter is an additional
mechanism, thrombolytic agents being less fibrin and more
fibrinogen specific than tenecteplase may induce more pro
nounced effects, because fibrinogenolysis can be expected
to further improve cerebral microcirculatory reperfusion.
Further experimental studies are warranted to test this
hypothesis.
Brain region Untreated Treated
Total forebrain 28±13% 7±6%*
Cerebral cortex 27±14% 8±1%*
Basal Ganglia 63±26% 15±20%*
Brainstem 26±26% 2±3%*
Thrombolytic treatment 
of noreflow after 15 min cardiac arrest
Values are crosssectional areas (±SEM) of noreflow in percent
of total brain, * — p<0.05. Data taken from [52].
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